Literature DB >> 10589362

Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis.

C Antoni1, J R Kalden.   

Abstract

Infliximab, a chimeric anti-TNF alpha antibody, showed in two double-blind placebo-controlled trials efficacy in combination with methotrexate (MTX) in patients with severe rheumatoid arthritis (RA). Whereas in the first trial low-dose MTX or placebo was compared to infliximab alone and in combination, the second trial compared infliximab to placebo in patients with active RA despite maximal tolerated MTX treatment. Infliximab showed synergistic effects in combination with MTX. The immunogenicity of infliximab was reduced by the combination. Infliximab in combination with high-dose MTX is effective and safe in long-term treatment up to 54 weeks.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10589362

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


  10 in total

Review 1.  Combination therapy in rheumatoid arthritis.

Authors:  S Bingham; P Emery
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Premedication prevents infusion reactions and improves retention rate during infliximab treatment.

Authors:  Francesca Bartoli; Cosimo Bruni; Laura Cometi; Jelena Blagojevic; Ginevra Fiori; Lorenzo Tofani; Felice Galluccio; Daniel E Furst; Marco Matucci Cerinic
Journal:  Clin Rheumatol       Date:  2016-07-19       Impact factor: 2.980

3.  Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins.

Authors:  Jean Lee; Hongjin Ma
Journal:  AAPS J       Date:  2007-05-25       Impact factor: 4.009

4.  The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.

Authors:  Fiona A Harding; Marcia M Stickler; Jennifer Razo; Robert B DuBridge
Journal:  MAbs       Date:  2010-05-01       Impact factor: 5.857

5.  Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease.

Authors:  R D Garman; K Munroe; S M Richards
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

6.  Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.

Authors:  L B A van de Putte; R Rau; F C Breedveld; J R Kalden; M G Malaise; P L C M van Riel; M Schattenkirchner; P Emery; G R Burmester; H Zeidler; H M Moutsopoulos; K Beck; H Kupper
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

Review 7.  Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.

Authors:  Kalle J Aaltonen; Liisa M Virkki; Antti Malmivaara; Yrjö T Konttinen; Dan C Nordström; Marja Blom
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

8.  A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications.

Authors:  X Chen; T P Hickling; P Vicini
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-09-03

9.  Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials.

Authors:  Tim Pickles; Robin Christensen; Lai-Shan Tam; Lee S Simon; Ernest H Choy
Journal:  Rheumatol Adv Pract       Date:  2018-10-17

10.  Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study.

Authors:  Thomas D Gilbert; Daniel Smith; Daniel A Ollendorf
Journal:  BMC Musculoskelet Disord       Date:  2004-10-14       Impact factor: 2.362
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.